– Results demonstrate melanocortin agonists may represent a new therapeutic avenue to treat diabetic nephropathy – Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN),…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.